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Abstract: Bacterial resistance is a growing global concern necessitating the discovery and development of antibiotics effective against the drug-resistant bacterial strain. Previously, we reported
a cyclic antimicrobial peptide [R4 W4 ] containing arginine (R) and tryptophan (W) with a MIC of
2.67 µg/mL (1.95 µM) against methicillin-resistant Staphylococcus aureus (MRSA). Herein, we investigated the cyclic peptides [R4 W4 ] or linear (R4 W4 ) and their conjugates (covalent or noncovalent)
with levofloxacin (Levo) with the intent to improve their potency to target drug-resistant bacteria.
The physical mixture of the Levo with the cyclic [R4 W4 ] proved to be significantly effective against
all strains of bacteria used in the study as compared to covalent conjugation. Furthermore, the
checkerboard assay revealed the significant synergistic effect of the peptides against all studied
strains except for the wild type S. aureus, in which the partial synergy was observed. The hemolysis
assay revealed less cytotoxicity of the physical mixture of the Levo with [R4 W4 ] (22%) as compared
to [R4 W4 ] alone (80%). The linear peptide (R4 W4 ) and the cyclic [R4 W4 ] demonstrated ~90% and
85% cell viability at 300 µg/mL in the triple-negative breast cancer cells (MDA-MB-231) and the
normal kidney cells (HEK-293), respectively. Similar trends were also observed in the cell viability
of Levo-conjugates on these cell lines. Furthermore, the time-kill kinetic study of the combination
of [R4 W4 ] and Levo demonstrate rapid killing action at 4 h for MRSA (ATCC BAA-1556) and 12 h
for E. coli (ATCC BAA-2452), P. aeruginosa (ATCC BAA-1744), and K. pneumoniae (ATCC BAA-1705).
These results provide the effectiveness of a combination of Levo with cyclic [R4 W4 ] peptide, which
may provide an opportunity to solve the intriguing puzzle of treating bacterial resistance.
Keywords: antibacterial resistance; cyclic antimicrobial peptides; checkerboard assay; drug-resistant
bacteria; combination therapy
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1. Introduction
Antimicrobial resistance (AMR) is a growing global concern that has caused prolonged
treatment for many common infections [1]. Overuse of antibiotics for the treatment of bacterial infections has promoted the development of antibacterial resistance genes, rendering
many antimicrobial treatments ineffective after a short period [2]. Methicillin-resistant
Staphylococcus aureus (MRSA) is a Gram-positive bacteria showing increased antibiotic
resistance. MRSA poses an enormous threat to the medical field, causing over 60% of
Staphylococcal infections in the intensive care unit [3]. In addition, the antibiotics developed to combat the diseases caused by drug-resistant bacteria, such as daptomycin, have
already shown resistance to MRSA strains [4]. Besides, the emergence of different strains of
bacteria having varying susceptibility to existing antibiotics challenges the use of a single
antibiotic for the recalcitrant bacteria, necessitating a combination of antibiotics showing
synergistic activity [5–9].
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As antimicrobial resistance increases, there is a prominent need for other means of
treatment; a promising area of success is antimicrobial peptides (AMPs) [3,10]. Antimicrobial peptides were first discovered in the 1980s from natural sources comprising sequences
containing 4 to 50 amino acid residues chiefly composed of cationic and hydrophobic
residues [11,12]. AMPs utilize their amphipathic structure to target a bacteria’s lipopolysaccharide layer, binding to the lipid components and the phospholipid groups of a bacteria’s
cell membrane. This mechanism causes a bacteria’s cell membrane lysis, rendering it immobile [5,13,14]. Although much scientific literature points to their tremendous potential, only
a few limited peptide-based antibiotics have been granted regulatory approval. Several
reasons for this limited bench to bedside translation are attributed due to their associated toxicity to mammalian cells [15] and low stability [16–18]. Synthetic antimicrobial
peptides (SAMPs) offer several advantages to conventional AMPs, such as low toxicity,
cost-effectiveness, and highly potent antibacterial activity [19,20]. Several research groups,
including ours, seek to investigate the usefulness of synthetic antimicrobial peptides to
combat this global health threat [21,22].
Previously, our lab reported a cyclic peptide containing four tryptophan (W) and
arginine (R) amino acids [R4 W4 ] as a synthetic antimicrobial peptide showing potent antibacterial activity against clinically resistant bacterial strains [23]. In particular, it showed
a minimum inhibitory concentration (MIC) of 2.67 µg/mL (1.95 µM) against MRSA (ATCC
43300) and 42.8 µg/mL (31.3 µM) against P. aeruginosa (PAO1) [24]. In addition, the time-kill
studies revealed that [R4 W4 ] and tetracycline combination exhibited bactericidal activity
against MRSA and E. coli (ATCC 35218). Furthermore, we synthesized several analogs of
[R4 W4 ] to obtain a structure-antibacterial activity. We deduced that the addition of more
than nine amino acids or lower than six amino acids in a cyclic ring resulted in low antibacterial potency compared to [R4 W4 ]. It was concluded that [R4 W4 ], [R3 W4 ], and [R4 W3 ]
peptides showed similar potency with a MIC value of ~2.97 µg/mL (~2.1 µM) [24]. Furthermore, a combination of [R4 W4 ] alone and in combination with current first-line antibiotics
(isoniazid or pyrazinamide) showed efficacious in treating Mycobacterium tuberculosis (M.
tb) inside human granulomas [25].
Antibiotic-peptide conjugates or antibiotic hybrids have been designed, evaluated,
and found to be more efficacious to treat pathogenic bacteria compared to the individual
antibiotics or peptides [26,27]. However, conjugates were also reported with lower potency
compared to antibiotics due to the covalent linkage between them and their incomplete
hydrolysis to afford interaction with the drug target. For example, [R4 W4 ] was conjugated
through an amide bond using lysine as a linker with the levofloxacin (Levo) to synthesize
Levo-[W4 R4 K] conjugate to generate enhanced potency against MRSA and other Gramnegative bacteria. However, conjugation resulted in a decrease in antibacterial activity. For
instance, [R4 W4 K]-levofloxacin-Q conjugate showed a MIC value of 32 µg/mL against
MRSA and >128 µg/mL against Klebsiella pneumonia, whereas the physical mixture of
[R4 W4 ] and Levo showed a MIC of 8 µg/mL against MRSA and 32 µg/mL against Klebsiella
pneumonia [28–30]. These outcomes suggested the stability of conjugate, which impacted
their individual activity as suggested by the physical mixture of Levo and [R4 W4 ]. In
a different study, Levo/Indolicidin was conjugated with a transporter peptide using an
amide and ester linkage, concluding that the conjugate containing amide linkage presented
less activity compared to the ester linkage [31]. In these studies, the carboxylic functionality
of Levo, which is the key structural element responsible for antibacterial activity, was
exploited to synthesize antibiotic peptide conjugate through amide bond [23,31]. The
amide linkage’s overall stability, especially under in-vitro experimental conditions, could
have inhibited the release of Levo, and ultimately, favorable interaction with the target
pathogen resulted in a decrease in the potency of the Levo-[R4 W4 ] conjugate. Therefore,
we hypothesized to synthesize the Levo-[R4 W4 ] conjugate using an ester linkage, which is
prone to undergo hydrolysis in physiological conditions to release peptide and antibiotics to
exert a synergistic activity. Given the potency and broad-spectrum antibacterial activity of
individual Levo and peptides against MRSA, there is a strong probability of effective syner-
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gistic action by complementing each other’s unique mode of action to provide compounds
against multi-drug resistant strain of MRSA. Several studies demonstrated the synergism of
AMPs and conventional antibiotics [32,33]. In addition, we envisioned that the multifaceted
mode of action of the conjugate poses a challenging task for the target pathogen to suppress
or subvert antibacterial action and evolve to be immune to the treatment.
In this report, the antibacterial activity of combination (covalent or physical mixture)
or individual compound (Levo and peptides) was determined against a panel of eight
bacterial strains by including one resistant strain of each type of bacteria. We sought to
determine the synergistic activity of the physical mixture using a checkerboard assay. The
cytotoxicity profile of all test compounds (Levo and peptide alone, chemical conjugates, and
physical combination) was assessed by measuring the lytic activity against human red blood
cells. Finally, we determined the time-kill kinetics of the studied antibacterial compounds.
These studies will provide a better understanding of using a combination of antibiotics and
antibacterial peptides to treat infections caused by multi-drug resistant bacteria.
2. Results and Discussion
2.1. Synthesis and Purification of the Compounds
The synthesis of linear (R4 W4 ) and cyclic [R4 W4 ] peptides were performed using
Fmoc/tBu solid-phase peptide chemistry as reported earlier. Scheme 1 depicts the synthesis of cyclic peptides conjugated with Levo. The design of synthesis of Levo conjugates with
antibacterial peptide was achieved by substituting one arginine residue with lysine to afford to couple a linker, 10-hydroxy decanoic acid (10-HDA), to the side chain of lysine. This
linker contains 10 carbons (C10 ) to provide sufficient spacer from antibacterial peptide sidechain residues to avoid steric hindrance to assist in the conjugation of Levo and contribute
to overall hydrophobicity. Due to the use of an unprotected OH group in 10-HDA during coupling to peptidyl resin using 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU) and N, N-diisopropylethylamine (DIPEA), a urea (uronium)
adduct at the OH group of conjugated decanoic acid was formed with the peptide, which reduced the availability of the OH group for further conjugation with Levo. It was confirmed
due to an increase of mass with ~99 dalton in the MALDI mass spectrum for the formation
of uronium adduct in the peptide (Supplementary Information). An ester linkage was
generated between the OH group of the linker and COOH of Levo using HBTU, DIPEA,
and 4-dimethylaminopyridine (DMAP) as coupling and activating reagents (Scheme 1).
Ester linkage was susceptible to esterase under physiological conditions for faster hydrolysis and release of drug from conjugates [34]. Figure 1 shows the chemical structures of
all the peptides and conjugates used in these studies. All the peptides and conjugates
were fully characterized using matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry and purified using reverse-phase high-performance
liquid chromatography (RP-HPLC) and were >95% pure as analyzed by analytical HPLC
(Supplementary Information). The Supplementary Material provides MALDI-TOF characterization data of peptides and conjugates.
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Figure 1. Chemical structures of synthesized peptides and conjugates.
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2.2. Antibacterial Activity
The antibacterial activity of synthesized peptides, conjugates, and their physical mixture
are reported in Table 1. Levo and cyclic peptide [R4 W4 ] showed a similar efficacy against
S. aureus (ATCC 29213) and MRSA (ATCC BAA-1556) with a MIC of 3.13 µg/mL (2.28 µM),
which is consistent with reported MICs [23]. The linear peptide (R4 W4 ) was two-fold less
active against both Gram-positive strains with a MIC of 6.25 µg/mL (4.51 µM). Cyclic peptide
[R4 W4 ] exhibited good activity (MIC = 6.25–12.5 µg/mL) against all the tested strains of
E. coli and K. pneumonia. However, Levo displayed mild activity (MIC = 25–50 µg/mL)
(69.18–138.36 µM) against E. coli and K. pneumonia. Similar to previous reports, Levo was
highly active against both the strains of P. aeruginosa with a MIC of 0.78 µg/mL (2.16 µM) [30].
[R4 W4 ] showed similar activity against both strains of P. aeruginosa with a MIC of 12.5 µg/mL
(9.11 µM). R4 W4 was found to be moderately active against all tested strains of Gram-negative
bacteria with a MIC of 25–50 µg/mL (18.03–36.06 µM). Interestingly, contrary to peptide alone,
the linear peptide (R4 W4 ) conjugate with Levo, (Levo-C10 -KR3 W4 ) showed two-fold higher
activity against S. aureus and MRSA (MIC = 12.5 µg/mL (6.67 µM)) as compared to cyclic
peptide Levo conjugate [Levo-C10 -KR3 W4 ] (MIC = 25–50 µg/mL (13.45–26.90 µM)). A similar
conjugate of these antibacterial peptides containing Levo with amide linkages; (R4 W4 K-Levo)
and [R4 W4 K-Levo] demonstrated higher MICs 32–128 µg/mL (~16.75–66.35 µM) against
MRSA and K. pneumoniae [30]. The use of ester linkage slightly improved potency in these
newly synthesized conjugates during the in-vitro assay. Very interesting, the ester bond
conjugates showed one to two-fold higher potency as compared to amide bond conjugate.
In addition, in some instances, it was found that linear peptide ester conjugate showed
one-fold higher potency as compared to cyclic peptide conjugates, e.g., S. aureus, MRSA,
and K. pneumoniae (ATCC 13883), which may be due to easier hydrolysis of conjugate to
release linear peptide and Levo as compared to hydrolysis of cyclic constrained peptide
conjugate. Furthermore, both the covalent conjugates of Levo with peptides showed mild
to moderate activity (MIC = 25–100 µg/mL (~13.34–53.79 µM)) against all tested Gramnegative strains. The conjugates may be more effective during in vivo studies where the ester
linkage will release both the peptide and Levo for antibacterial activity. In the conjugates, the
COOH of Levo has been used in the ester linkage, which is part of the pharmacophore for
antibacterial activity.
The addition of bulky peptides with the COOH group of Levo provides further steric
hindrance. Furthermore, the conjugates also provided specific interaction with bacterial
membrane for membranolytic activity as compared to peptide alone. Therefore, these
conjugates did not show enhanced potency as compared to Levo or peptide alone.
Nonetheless, a close examination of antibacterial activity in Table 1 revealed that the
physical mixture of Levo with either linear or cyclic peptides (R4 W4 or [R4 W4 ]) exerted
high antibacterial activity against all tested strains as compared to Levo and peptides alone
and their covalent conjugates. The physical mixture was performed at the 1:1 w/w ratio
that contains 3:85:1 molar ratio of Levo and peptides. The physical mixture of Levo and
linear peptide (R4 W4 ) exhibited good activity with a MIC of 3.13 µg/mL against both S.
aureus and MRSA. However, for the physical mixture of Levo and cyclic peptide [R4 W4 ],
a similar trend of activity against S. aureus (MIC = 3.13 µg/mL) was observed, but there
was a one-fold increase in MIC (6.25 µg/mL) against MRSA (Table 1). Noticeably, physical
mixture of Levo and peptides exerted the killing action against both strains of E. coli at
a 2 to 4-fold lesser MICs (12.5–25 µg/mL) as compared to Levo (MIC = 50 µg/mL) but
2-fold higher MICs (6.25–12.50 µg/mL) against peptides alone. For P. aeruginosa, while
the physical mixture of Levo and peptides displayed activity at one-fold higher MICs
(0.78–1.56 µg/mL) as compared to Levo (0.78 µg/mL) alone, a significant decrease in MIC
was observed as compared to peptides (12.5–25 µg/mL) alone and their covalent conjugates
with Levo (≥100 µg/mL). Similarly, compared to Levo alone (MIC = 25–50 µg/mL), the
physical mixture exhibited around four-fold decrease in MICs (12.5–25 µg/mL) against
imipenem-resistant K. pneumonia. Therefore, it was concluded that the physical combination
is more potent than the chemical conjugates of Levo and antibacterial peptides containing
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either an amide bond or an ester linkage due to higher molar ratio of Levo. Considering the
exciting outcomes of the physical mixture, we further investigate the synergistic activity of
Levo and peptides described below.
Table 1. Antibacterial activity of synthesized compounds.
MIC (µg/mL) (µM) a
Bacterial Strain

Levo

(R4 W4 )

[R4 W4 ]

(Levo-C10 KR3 W4 )

[Levo-C10 KR3 W4 ]

Levo + (R4 W4 ) b

Levo + [R4 W4 ] b

S. aureus
(ATCC 29213)

3.13
(8.66)

6.25
(4.51)

3.13
(2.28)

12.5
(6.67)

25
(13.45)

3.13

3.13

S. aureus
(ATCC BAA-1556) c

3.13
(8.66)

6.25
(4.51)

3.13
(2.28)

12.5
(6.67)

50
(26.90)

3.13

6.25

E. coli
(ATCC 25922)

50
(138.36)

25
(18.03)

6.25
(4.55)

50
(26.68)

50
(26.90)

12.5

12.5

E. coli
(ATCC BAA-2452) d,e

50
(138.36)

50
(36.06)

12.5
(9.11)

50
(26.68)

100
(53.79)

25

12.5

P. aeruginosa
(ATCC 27883)

0.78
(2.16)

25
(18.03)

12.5
(9.11)

100
(53.36)

100
(53.79)

1.56

1.56

P. aeruginosa
(ATCC BAA-1744) e

0.78
(2.16)

25
(18.03)

12.5
(9.11)

100
(53.36)

>100
(>53.79)

1.56

0.78

K. pneumoniae
(ATCC 13883)

25
(69.18)

50
(36.06)

12.5
(9.11)

25
(13.34)

50
(26.90)

25

12.5

K. pneumoniae
(ATCC BAA-1705) f

50
(138.36)

25
(18.03)

12.5
(9.11)

50
(26.68)

50
(26.90)

12.5

12.5

a

Minimum inhibitory concentration (MIC). Values in the parenthesis are MICs in unit of micromolar. b Physical
mixture composed of Levofloxacin: Peptide molar ratio of 3.85:1 (1:1; w/w). c Methicillin, d New Delhi Metallobeta-lactamase (NDM-1) positive, e Carbapenem, and f imipenem resistant bacterial strains.

2.3. Combination Studies Using Levo and Peptides
Since the physical mixture exhibited a significantly higher potency against almost
all bacterial strains used in the study as compared to covalent conjugates, therefore, a
checkerboard assay was performed to examine if the combination of antibacterial peptides
with Levo has a synergistic or additive effect on antibacterial activity. Both the susceptible
and antibiotic-resistant strains of bacteria were used in this study. Table 2 revealed the
antibacterial activity of the combination of Levo and peptides (linear or cyclic). As the data
suggest, linear peptide (R4 W4 ) showed partial synergy with Levo for S. aureus (FICI = 0.748)
and MRSA (FICI = 0.999). However, the combination of Levo and cyclic peptide [R4 W4 ]
displayed complete synergism (FICI = 0.498) against MRSA. In contrast, the combination
of Levo and linear peptide (R4 W4 ) was found to be less effective against Gram-negative
strains with a non-significant synergism was observed for E. coli (ATCC 25922) (FICI = 1),
P. aeruginosa (ATCC 27883) (FICI = 1.062), and K. pneumoniae (ATCC 13883) (FICI = 1.25).
However, a partial synergistic activity (FICI = 0.562) was observed against carbapenemresistant P. aeruginosa (ATCC BAA-1744).
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Table 2. Checkerboard assay using a combination of Levo and peptides.
FICI a

MIC in Combination (µg/mL)
Bacterial Strain

Levo/(R4 W4 )

Levo/[R4 W4 ]

Levo + (R4 W4 )

Interactive
Category

Levo + [R4 W4 ]

Interactive
Category

S. aureus
(ATCC 29213)

1.56/1.56

0.78/1.56

0.748

Partial synergy

0.748

Partial synergy

S. aureus
(ATCC BAA-1556)

1.56/3.13

0.78/0.78

0.999

Partial synergy

0.498

Synergy

E. coli
(ATCC 25922)

25/12.5

6.25/1.56

1

Indifference

0.374

Synergy

E. coli
(ATCC BAA-2452)

25/12.5

3.13/3.13

0.75

Partial synergy

0.313

Synergy

P. aeruginosa
(ATCC 27883)

0.78/1.56

0.15/1.56

1.062

Indifference

0.317

Synergy

P. aeruginosa
(ATCC BAA-1744)

0.39/1.56

0.07/1.56

0.562

Partial Synergy

0.214

Synergy

K. pneumoniae
(ATCC 13883)

25/12.5

6.25/3.13

1.25

Indifference

0.500

Synergy

K. pneumoniae
(ATCC BAA-1705)

25/12.5

12.5/1.56

1

Indifference

0.374

Synergy

a

The Fractional Inhibitory concentration Index (FICI) was calculated according to the equation: FICA + FICB
= (MIC Drug A in combination/MIC Drug A alone) + (MIC Drug B in combination/MIC Drug B alone). FICI
was interpreted as follows: FICI < 0.5, synergy; 0.5 ≤ FICI < 1, partial synergy; 1 ≤ FICI < 4, additive effect or
indifference; 4 ≤ FICI antagonism.

Interestingly, the combination of Levo and cyclic peptide [R4 W4 ] showed synergy
against all the studied bacterial strains except for S. aureus (ATCC 29213), which exhibited partial synergy (FICI = 0.748) (Table 2). The results of the synergistic study explicitly revealed the effectiveness of the physical mixture over Levo and peptide alone and
their chemical conjugates. This observation can be further investigated for other potent
membranolytic antibiotics such as daptomycin, polymyxin, telavancin, oritavancin, and
dalbavancin [5]. Further exploration of these studies can result in lead combinations that
can be translated for in-vivo studies in the future.
2.4. Hemolytic Study
We designed an experiment to conduct the hemolytic effect of the Levo, peptides
(linear and cyclic), covalent conjugates, and physical mixtures of Levo and peptides. The
percentage of hemolysis for each test compound observed at the highest experimental
concentration (500 µg/mL) is presented in Figure 2. While cyclic peptide [R4 W4 ] showed
significant hemolytic activity (~80%) moderate hemolysis was observed for linear peptide
(~38%). The covalent conjugates of Levo and peptides (Levo-C10 -KR3 W4 ) and [Levo-C10 KR3 W4 ]) exhibit low hemolysis as compared to peptide alone. Interestingly, the physical
mixture of Levo and peptides (500 µg/mL (1:1; w/w)) showed negligible toxicity with ~10%
and ~22% hemolysis was observed for Levo + (R4 W4 ) and Levo + [R4 W4 ], respectively.
This significant decrease in hemolytic activity can be attributed to the lowered dose of
the cyclic peptide without compromising its antibacterial potency. The results indicate
that further exploration of different combinations of antibiotics and the cyclic antibacterial
peptides can lead to some breakthrough discovery in antibiotic development against
drug-resistant strains.
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2.6. Time Kill Kinetics
We conducted a kill kinetic assay of Levo and peptides (linear or cyclic) alone and
their physical mixture against drug-resistant bacterial strains of S. aureus (ATCC BAA-1556),
E. coli (ATCC BAA-2452), P. aeruginosa (ATCC BAA-1744), and K. pneumoniae (ATCC BAA1705). The purpose of this study was to investigate the time-dependent killing action of the
test compounds against antibiotic-resistant strains. Figure 4A reveals that the cyclic [R4 W4 ]
completely eradicated the growth of MRSA in 8 h, as compared to Levo. In contrast, when
cyclic [R4 W4 ] mixed with Levo, it significantly inhibited the growth (~90%) of MRSA in
4 h, pointing to the physical mixture’s effectiveness compared to the peptide or the Levo
alone. However, the linear peptide (R4 W4 ) could not achieve significant growth inhibition
even after 12 h, clearly indicating the potency of cyclic peptide over its linear counterpart.
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peptide or the Levo alone. However, the linear peptide (R4W4) could not achieve signifiInterestingly, there was an apparent time reduction when we compared the cyclic
cant growth inhibition even after 12 h, clearly indicating the potency of cyclic peptide over
[R4 W4 ] to the Levo. Overall, the results demonstrated the rapid killing action of cyclic
its linear counterpart.
peptide alone and in a physical mixture with Levo (Figure 4). Although, kill kinetics studies
Interestingly, the physical mixture of the linear peptide with Levo could not exert
are frequently conducted to test the effectiveness of the antibacterial agents. However,
efficient time-dependent killing of the MRSA (Figure 4A). Similar trends were observed
to the best of our understanding, this is the first report describing the kill kinetics of the
for other bacterial strains used in the studies. For instance, in the case of E. coli, the cyclic
antibiotic with the synthetic cyclic antibacterial peptide [R4 W4 ]. We can safely speculate
[R4W4] exhibited a complete inhibition after 12 h. Still, the physical
mixture of cyclic pepfrom this study that the physical combination of the potent antibiotic with the promising
tide [R4W4] with Levo showed almost complete inhibition within 4 h of exposure, showing
antibacterial peptide molecules can make the drug-resistant strains sensitive.
the superiority of the physical mixture compared to the peptide or the antibiotic alone
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(Figure 4B). The linear peptide (R4W4) could not significantly inhibit the growth of both P.
aeruginosa (ATCC BAA-1744) and K. pneumoniae (ATCC BAA-1705). However, cyclic pep10 of 15
tide [R4W4] exhibited a remarkable growth inhibition activity against both Gram-negative
bacterial strains (Figure 4C,D).

Figure
killstudy
studyofofthe
the
test
compounds
against
drug-resistant
bacterial
strains
Figure 4.
4. Time-dependent
Time-dependent kill
test
compounds
against
drug-resistant
bacterial
strains
of
of
(A)
aureus
(ATCC
BAA-1556),
(B)
coli(ATCC
(ATCC
BAA-2452),
(C)
aeruginosa
(ATCC
BAA-1744),
(A)
S.S.
aureus
(ATCC
BAA-1556),
(B)
E.E.
coli
BAA-2452),
(C)
P.P.
aeruginosa
(ATCC
BAA-1744),
and
K.pneumoniae
pneumoniae(ATCC
(ATCC
BAA-1705).
represent
the results
of the experiment
perand (D)
(D) K.
BAA-1705).
TheThe
datadata
represent
the results
of the experiment
performed
formed
in
triplicate.
in triplicate.

3. Materials
and Methods
Interestingly,
there was an apparent time reduction when we compared the cyclic
3.1.
Chemicals
and Reagents
4W
4] to the Levo.
Overall, the results demonstrated the rapid killing action of cyclic pep[R
tide alone
and
in
a
mixture
withbuilding
Levo (Figure
4).preloaded
Although,2kill
kinetics resin,
studies
The Fmoc/tBuphysical
protected
amino acid
blocks,
chlorotrityl
are
conducted
to test
thepurchased
effectiveness
the antibacterial
agents. However,
andfrequently
peptide synthesis
reagents
were
fromofChem-impex
International
Inc, (Wood to
the
best
our Solvents
understanding,
is thewere
firstpurchased
report describing
the kill
kinetics
of the
Dale,
IL, of
USA).
and otherthis
reagents
from Millipore
Sigma
(Milwaukee, WI, USA).
cell culture
supplies
were purchased
from
Corning
antibiotic
with All
the the
synthetic
cyclic
antibacterial
peptide [R
4W4].
We can(Christiansburg,
safely speculate
VA, USA)
and Fisher
Scientific
(Waltham,
MA,ofUSA).
The human
triple-negative
breast
from
this study
that the
physical
combination
the potent
antibiotic
with the promising
cancer cell line
(MDA-MB-231,
No. HTB-26),
and normal
kidney
cell line (HEK-293,
antibacterial
peptide
moleculesATCC
can make
the drug-resistant
strains
sensitive.
ATCC No. CRL-1573) were purchased from ATCC (Manassas, VA, USA). CellTiter 96®
AQueous
One
Solution
cell proliferation assay (MTS) was purchased from Promega (Madi3.
Materials
and
Methods
son, WI, USA). Cell culture was carried out at 37 ◦ C with 5% CO2 in a Forma incubator
3.1. Chemicals and Reagents
using a T-75 flask.
The Fmoc/tBu protected amino acid building blocks, preloaded 2 chlorotrityl resin,
3.2. Design
andsynthesis
Synthesis reagents
of Levo-[Wwere
Conjugate from Chem-impex International Inc,
and
peptide
4 R3 K]purchased
(Wood
Dale,
IL,
USA).
Solvents
and
other
reagents were
purchased
fromsynthesis
Millipore
Sigma
The peptides were synthesized using Fmoc/tBu
solid-phase
peptide
(SPPS)
(Milwaukee,
WI,
USA).
All
the
cell
culture
supplies
were
purchased
from
Corning
(Chriswith protected amino acids building blocks as described in Scheme 1, and the procetiansburg,
VA, previously
USA) and Fisher
Scientific
(Waltham,
MA,
Theofhuman
dure reported
from our
lab [23,30].
In brief,
theUSA).
sequence
linear triple-negaprotected
tive
breast
cancer
cell line (MDA-MB-231, ATCC No. HTB-26), and normal
kidney cellon
line
peptide
(NH
was assembled
2 -R(Pbf)-R(Pbf)-R(Pbf)-W(Boc)-W(Boc)-W(Boc)-W(Boc))
Trp(Boc)-2-chlorotrityl
on 0.3 mmol
A lysinefrom
(K) residue
coupled using
(HEK-293,
ATCC No.resin
CRL-1573)
werescale.
purchased
ATCCwas
(Manassas,
VA, DdeUSA).
Lys(Fmoc)-OH
(4 equiv.),One
HBTU
(4 equiv.),
(8 equiv.)
in the(MTS)
DMF to
thepurchased
peptidyl resin
CellTiter
96® AQueous
Solution
cellDIPEA
proliferation
assay
was
from
for
2
h,
followed
by
Fmoc
deprotection
using
20%
piperidine
in
DMF
(10
min
× 2CO
times)
Promega (Madison, WI, USA). Cell culture was carried out at 37 °C with 5%
2 in a
to provide
NH2 group.
Forma
incubator
using a The
T-75amino
flask. group was coupled with 10-hydroxydecanoic acid
(10-HDA, 4 equiv.) using HBTU (4 equiv.) and DIPEA (8 equiv.) in DMF for 3 h. Subsequently, Levo was conjugated via ester bond using a carboxylic group of Levo and the
available hydroxyl group on peptidy resin as depicted in Scheme 1. Levo conjugation
with the linear peptide (R4 W4 ) was done according to the conditions described by Ghaffar
et al. [31] using HBTU (4.0 eq.)/DIPEA (4.2 eq.), and DMAP (0.1 eq.) on the solid phase.
Dde group at N terminus was removed by treating peptidyl resin with 2%hydrazine hydrate in DMF (10 min × 2 times) followed by DMF wash (3 times). After linear peptide
containing Levo was assembled on the resin, a mixture of dichloromethane (DCM):2,2,2-
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trifluoroethanol (TFE): acetic acid (AcOH) (7:2:1 v/v/v, 150 mL) was added to remove the
resin, followed by cyclization of side-chain protected peptide overnight under nitrogen
using 1,3-diisopropylcarbodiimide (DIC)/1-hydroxy-7-azabenzotriazole (HOAt) (0.3 mmol,
3 equiv.) according to the protocol published by Oh et al. [24]. A test cleavage using a
freshly prepared cleavage cocktail of reagent R (90% trifluoroacetic acid (TFA): 2% anisole:
3% thioanisole, and 2–3 mg of dithiothreitol (DTT)) for a small amount of peptidyl resin
confirmed the cyclization by MALDI-TOF mass spectrometry. The reaction mixture was
evaporated to a minimal amount followed by treatment with reagent R for 6 h and precipitation of peptide using the ice-cold diethyl ether. The precipitated conjugate was purified
using RP-HPLC. A gradient of water and acetonitrile (ACN) in 0.1% trifluoroacetic acid
(TFA, v/v) was mobile phase used to purify the peptide on a Shimadzu HPLC system (LC20AP) (Canby, OR, USA) using a C18 preparatory column (00G-4436-P0-AX Gemini Prep
C18, 10 µm particle size, 250 × 21.2 mm, and 110 Å pore size). HPLC fractions showing
similar mass were lyophilized to obtain powdered peptides (≥95% purity) used in bioassay.
The cyclized peptide [R4 W4 ] was obtained in ~40% yield and conjugates of Levo with cyclic
peptide [Levo-C10 -KR3 W4 ] or linear peptides (Levo-C10 -KR3 W4 ) were obtained with a
lower yield (~20%). MALDI-TOF (m/z) for synthesized compounds; linear peptide (R4 W4 ),
[C68 H90 N24 O9 ]: calcd, 1386.7323; found, 1388.0632 [M + 2H]+ ; for cyclic peptide [R4 W4 ],
[C68 H88 N24 O8 ]: calcd, 1368.7217; found, 1368.0730 [M]+ ; for linear conjugate (Levo-C10 KR3 W4 ), [C96 H128 FN25 O14 ]: calcd, 1874.0057; found, 1873.9719 [M]+ ; and cyclic conjugate
[Levo-C10 -KR3 W4 ], [C96 H126 FN25 O13 ]: calcd, 1855.9951; found, 1855.1249 [M]+ .
3.3. Antibacterial Activity
3.3.1. Bacterial Strains
The antibacterial activity of synthesized compounds was determined against a range
of susceptible and drug-resistant bacterial strains. The antibacterial activities of all test
compounds alone and in combination with Levo were evaluated against the following
bacterial strains; Staphylococcus aureus (ATCC 29213 and ATCC BAA-1556), Escherichia
coli (ATCC 25922 and ATCC BAA-2452), Pseudomonas aeruginosa (ATCC 27883 and ATCC
BAA-1744), and Klebsiella pneumoniae (ATCC 13883 and ATCC BAA-1705). All bacterial
strains employed in this study were procured from VWR International Inc (Pasadena,
CA, USA), and propagated as per the recommendation of the American Type Culture
Collection (ATCC).
3.3.2. Determination of Minimal Inhibitory Concentrations (MICs)
Antibacterial susceptibility testing was carried out using a standard microtiter dilution
method recommended by clinical and laboratory standard institute (CLSI) and measured
as minimum inhibitory concentration (MIC), the lowest peptide concentration that inhibited bacterial growth [35]. Briefly, cells were grown overnight at 37 ◦ C in the broth
recommended for each strain and were diluted in cation-adjusted Mueller–Hinton Broth
(CAMHB). An aliquot of an overnight culture of bacteria was diluted in 1mL normal saline
to achieve 0.5 McFarland turbidity (1.5 × 108 bacterial cell CFU/mL). A total of 60 µL of the
0.5 McFarland solution was added to 8940 µL of MH media (1/150 dilution). An amount
of 100 µL MH media was pipetted into the sterile plate wells except for the first row of the
plate. An amount of 200 µL of 100 µg/mL test compound was added by pipette into the
first row and serially diluted with the MH media sterile 96 wells using a multi-channel
pipette except the last row. An amount of 100 µL aliquot of bacteria solution was added
to each well, and the plate was incubated at 37 ◦ C for 18–24 h. All experiments were
performed in triplicate.
3.3.3. Checkerboard Assay
The checkerboard method was used to assess the MIC of Levo in combination with
antimicrobial peptides. The assay was conducted based on the broth microdilution method
in accordance with the CLSI protocols using cation-adjusted Mueller–Hinton broth [36,37].
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Levo and peptides were two-fold serially diluted in a horizontal and vertical orientation,
respectively, in a 96-well microtiter plate. The assay was performed by taking twice the
MICs of Levo and peptides alone determined against various bacterial strains as the highest
test concentration. Levo was tested as 11 point, 2-fold serial dilutions across the assay
plate (from 1–11) in combination with a 7 point, a 2-fold serial dilution of the peptides
down the assay plate. Two-fold serial dilution in row H (from 1–11) for Levo antibiotic
alone was performed to determine the MIC value for each test compound. In column
12 (A-G) down the assay plate, 2-fold serial dilution of the peptide alone was performed.
Then, 100 µL of test specimen (peptide and Levo alone or a peptide/Levo combination)
were inoculated with 100 µL of the bacterial suspension (1 × 105 CFU/mL). MH medium
was used as a negative control, and the peptide or Levo alone was used as a positive
control. After overnight incubation at 37 ◦ C, the MIC was defined as described above.
Synergistic interactions were expressed as the fractional inhibitory concentration index
(FICI), which was calculated as follows: FICI = FICa + FICb, where FICa and FICb are
the MICs of the peptides in the combination divided by the MICs of the peptides alone
and the MICs of the antibiotics in the combination divided by the MICs of the antibiotics
alone, respectively. FICI ≤ 0.5, 0.5 < FICI ≤ 1.0, and 1.0 < FICI ≤ 2.0 were defined as
synergy, addition, and indifference, respectively [38,39]. The results were collected from
3 independent experiments.
3.4. Hemolysis Assay
Hemolytic activity of Levo and peptides alone and in combination was determined
using human red blood cells (hRBC) purchased from BioIVT (Hicksville, NY, USA). The
hRBC were centrifuged for 15 min to remove the buffy coat and washed 3 times with
phosphate buffer saline (100 mM NaCl, 80 mM Na2 HPO4 , 20 mM NaH2 PO4 , pH 7.4). The
assay was conducted in triplicate by mixing 75 µL of peptide solution (2-fold serial dilution)
with 75 µL of a 4% (v/v) hRBC suspension in phosphate buffer saline. The plates were
incubated for 2 h at 37 ◦ C without agitation and centrifuged at 1000× g for 10 min. Aliquots
(100 µL) of the supernatant were transferred to 96-well plates, where hemoglobin release
was measured spectrophotometrically at 567 nm. Percent hemolysis was calculated by the
following formula:
Percentage hemolysis = 100 × [(A − A0 )/(At − A0 )]
where A represents the absorbance of peptide sample at 567 nm and A0 and At represent
zero percent and 100% hemolysis determined in phosphate buffer saline and 1% Triton
X-100, respectively.
3.5. Cytotoxicity Assay
The in vitro cytotoxicity of the synthesized peptides, and their conjugates with Levo
was determined in the MDA-MB-231 and HEK-293 cell lines. The MDA-MB-231 and HEK293 cells were cultured in DMEM/F-12 (cat # 11330-032, Corning, VA, USA), 100 IU/mL
penicillin, and 100 IU/mL streptomycin supplemented with fetal bovine serum (FBS).
Approximately, 10,000 cells per 0.1 mL were seeded in each well in a 96-well plate using
a multichannel pipette and were allowed to adhere to the bottom of the plate for 24 h
in the incubator. After 24 h, the cells were inspected for their health and confluency.
Different concentrations of the peptides and their conjugates were added to each well in
triplicate and incubated for 48 h at 37 ◦ C in a humidified atmosphere of 5% CO2 . After 48 h,
20 µL of the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium (MTS) reagent was added to each well using a multichannel pipette. The
96-well plates were centrifuged at 1000 rpm for 1 min to ensure the settling of the MTS
reagent, and after that, the plates were incubated for additional 3 h. 96 well plate was
measured for absorbance at 490 nm using SpectraMax M2 microplate spectrophotometer
(Molecular Devices, LLC. San Jose, CA, USA) to determine cell viability. Non-Treated (NT)
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cells served as negative control whereas the DMSO 30% (v/v) was used as a positive control.
The% cell viability was calculated using the following formula;
% cell viability =

(OD value of cells treated with compounds) − (OD value of culture medium)
× 100
(OD value of control cells) − (OD value of culture medium)
3.6. Time-Kill Kinetics Assay
The time course of bacterial killing was studied by the exposure of overnight grown
cultures of antibiotic-resistant strains of MRSA (ATCC BAA-1556), E. coli (ATCC BAA2452), P. aeruginosa (ATCC BAA-1744), and K. pneumoniae (ATCC BAA-1705). Levo and
peptides alone and in combination at MIC were tested against the above-mentioned bacterial strains. Test tubes containing Mueller–Hinton (MH) broth supplemented with Levo and
peptides, alone and in combination, were inoculated with overnight grown bacterial culture
(1.5 × 108 CFU/mL) and incubated at 37 ◦ C. Aliquots were sampled at 0, 0.5, 1, 2, 4, 8,
and 12 h time points, then diluted and plated on the Muller–Hinton agar plate. After 24 h
incubation at 37 ◦ C, CFU count was performed using the standard formula. Untreated bacterial culture was used as a control. Data were obtained from 2 independent experiments
performed in triplicate.
4. Conclusions
The conjugates of Levo with a potent antibacterial peptide [R4 W4 ] were tested to
provide synergistic activity against selected strains of Gram-positive and Gram-negative
bacteria. The covalent conjugates of peptide and Levo were successfully synthesized,
characterized, and purified using MALDI-MS and RP-HPLC. The antibacterial activity of
the tested compound demonstrated a weaker antibacterial activity for covalent conjugates
as compared to combination (physical mixture/noncovalent) and Levo. Therefore, a
checkerboard assay was performed, which depicted a synergistic activity between cyclic
peptide and Levo. However, it was also worthy of observing that the physical mixture of
Levo with peptide, especially cyclic peptide, not only maintained the antibacterial potency
against drug-resistant P. aeruginosa (ATCC BAA-1744) and K. pneumoniae (ATCC BAA-1705)
but also significantly improved the antibacterial potency compared to the antibiotic or
the peptide alone. Synergistic studies revealed that the cyclic peptide showed remarkable
synergy with levofloxacin against all studied strains except for the wild-type strain of
S. aureus (ATCC 29213), in which the partial synergy was observed. Hemolytic assay results
showed that the hemolytic effect of cyclic peptide [R4 W4 ] significantly reduced in the
combination (physical mixture) with Levo without compromising its antibacterial potency.
(R4 W4 ), [R4 W4 ], and their conjugates with Levo were found not cytotoxic up to 200 µg/mL
to the MDA-MB-231 and HEK-293 cells, a much higher concentration than their MIC values.
Furthermore, the time-kill kinetic study results also point towards the effectiveness of
a combination of the potent antibiotic Levo with cyclic synthetic antimicrobial peptide
[R4 W4 ]. It can be speculated that further exploration of this combination approach can
lead to some breakthrough discovery in antibiotic development against drug-resistant
strains [40,41]. More studies are needed to translate this approach to the bedside.
Supplementary Materials: The following supporting information can be downloaded at: https://
www.mdpi.com/article/10.3390/antibiotics11030416/s1, which contains MALDI-TOF and analytical
HPLC data of synthesized compounds.
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